Market Access News | pharmaphorum

News

Before it has even launched, Eisai has filed to widen subcutaneous Leqembi's label to include starting as well as maintenance dosing in Alzheimer's.

News

A prominent critic of RFK Jr's approach to vaccination regulation, Dr Paul Offit, has been removed from an influential FDA advisory committee.

News

No fewer than nine former directors of the CDC have said every American should be alarmed at what is happening on HHS Secretary Kennedy's watch.

News

A Newcastle University project that gauges whether health technologies can deliver real changes to the NHS has claimed £22m in UK government funding.

News

Sanofi's BTK inhibitor Wayrilz has become the first drug in the class to be approved for rare platelet-busting disease immune thrombocytopenia.

News

Eisai and Biogen get FDA approval for subcutaneous Leqembi. Will it help stave off growing competition from Lilly's Kisunla in Alzheimer's treatment?